Clinical outcomes in pediatric acute lymphoblastic leukemia using modified BFM-95 protocol: 10-year study in Mexico city

Clicks: 3
ID: 317440
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #41 of 50 articles by views in jnci cancer spectrum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Although survival rates for acute lymphoblastic leukemia (ALL) in developed countries have reached up to 80%, outcomes remain considerably lower in emerging nations. This study aimed to evaluate the 10-year survival of pediatric patients with ALL treated at a public hospital using the HP 09 protocol, adapted from the BFM 95 protocol. METHODS: We included patients under 17 years of age diagnosed with ALL and treated with the HP 09 protocol between January 2010 and December 2020. Patients were stratified into three risk groups according to clinicobiological characteristics. RESULTS: A total of 253 patients were analyzed. The cohort demonstrated a 10-year overall survival (OS) rate of 58.1% (90.4 ± 4.8 months) and an event-free survival (EFS) rate of 56.9% (78.2 ± 5.0 months). By risk group, the 10-year OS was 41% in the high-risk group, 61.9% in the intermediate-risk group, and 85.7% in the standard-risk group. Corresponding 10-year EFS rates were 55.2%, 57.1%, and 59.7%. Cox regression analysis identified older age (>10 years; OR 2.11, CI 1.36 to 3, P=.001), leukocyte count >50 × 109/L (OR 1.89, CI 1.22 to 2.93, P=.004), and prior steroid exposure before diagnosis (OR 2.30, CI 1.16 to 4.58, P=.017) as significant predictors of relapse. CONCLUSIONS: This study highlights a substantial disparity in survival rates among pediatric patients with ALL in Mexico compared with international benchmarks. The gap likely reflects differences in chemotherapy efficacy, disease biology, and systemic healthcare limitations.
Reference Key
openalex_W7164751142 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Karina A Solis-Labastida, Rosa E. Valdez-Avilez, Salvador Atilano-Miguel, Jorge Alfonso Martín‐Trejo, Lourdes Barbosa-Cortés, Benito A Bautista-Martínez, Azalia Juárez-Moya, Zayra Hernández-Piñón
Journal jnci cancer spectrum
Year 2026
DOI
10.1093/jncics/pkag061
URL
https://doi.org/10.1093/jncics/pkag061
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.